Nexgard Spectra 75 mg / 15 mg Chewable Tablets for Dogs >15–30 kg

Dosage:
The veterinary medicinal product should be administered at a dose of 2.50 to 6.94 mg/kg
of afoxolaner and 0.50 to 1.39 mg/kg of milbemycin oxime in accordance with the following
table:
AN: 00196/2025Page 5 of 9
Number and strength of chewable tablet to be administeredBodyweight
of dog (kg)
NEXGARD
SPECTRA
9 mg/ 2
mg
NEXGARD
SPECTRA
19 mg/ 4
mg
NEXGARD
SPECTRA
38 mg/
8 mg
NEXGARD
SPECTRA
75 mg/ 15
mg
NEXGARD
SPECTRA
150 mg/ 30
mg
1.35–3.51>3.5–7.51>7.5–151>15–301>30–601
For dogs above 60 kg appropriate combinations of chewable tablets should be used.
To ensure a correct dosage, body weight should be determined as accurately as possible.
The chewable tablets should not be divided. Underdosing could result in ineffective use
and may favour resistance development.
Method of administration:
The tablets are chewable and palatable to most dogs. If the dog does not accept the
tablets directly they may be administered with food.
Treatment schedule:
The need for and frequency of re-treatment(s) should be based on professional advice and
should take into account the local epidemiological situation and the animal’s lifestyle.
Treatment of flea and tick infestations and gastrointestinal nematodes:
The veterinary medicinal product can be used as part of the seasonal treatment of fleas
and ticks (replacing treatment with a monovalent flea and tick product) in dogs with
diagnosed concurrent gastrointestinal nematode infestations. A single treatment is
effective for the treatment of gastrointestinal nematodes.
Treatment of demodicosis (caused by Demodex canis):
Administration of the veterinary medicinal product leads to a marked improvement of
clinical signs. Treatment should be continued until two negative skin scrapings are
obtained one month apart. Severe cases may require prolonged monthly treatments. As
demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any
underlying disease appropriately.
Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis):
Monthly administration of the veterinary medicinal product for two consecutive months.
Further monthly administrations may be required based on clinical assessment and skin
scrapings.
AN: 00196/2025Page 6 of 9
Treatment of ear mite infestations (caused by Otodectes cynotis):
A single dose of the veterinary medicinal product should be administered. A further
veterinary examination one month after the initial treatment may be recommended as
some animals may require a second treatment.
Prevention of heartworm disease:
The veterinary medicinal product kills Dirofilaria immitis larvae up to one month after their
transmission by mosquitoes, therefore the veterinary medicinal product should be
administered at regular monthly intervals during the time of the year when vectors are
present, starting in the month after the first expected exposure to mosquitoes.
Treatment should continue until 1 month after the last exposure to mosquitoes. To
establish a treatment routine, it is recommended that the same day or date be used each
month. When replacing another heartworm preventative product in a heartworm prevention
programme, the first treatment with the veterinary medicinal product should start on the
date when the former medication was due to have been administered.
Dogs living in heartworm endemic areas, or those which have travelled to endemic areas,
may be infested with adult heartworms. No therapeutic effect against adult Dirofilaria
immitis has been established. It is therefore recommended that all dogs 8 months of age or
more, living in heartworm endemic areas, should be tested for existing adult heartworm
infestation before being treated with the veterinary medicinal product for heartworm
prevention.
Prevention of angiostrongylosis:
In endemic areas, monthly administration of the veterinary medicinal product will reduce
the level of infection with immature adults (L5) and adults of Angiostrongylus vasorum in
the heart and lungs.
Prevention of thelaziosis:
Monthly administration of the veterinary medicinal product prevents establishment of
infection with adult Thelazia callipaeda eyeworm.